ABBV

The company exists because of a patent cliff that was visible years in advance. Abbott split itself in two in 2013, separating a diversified medical products business, which kept the Abbott name and focused on diagnostics, devices, nutrition, and generic drugs, from a pure-play pharmaceutical business, which became AbbVie. The logic was that the two halves had different growth profiles, different investor bases, and different risks, and that the looming expiration of Humira's exclusivity was a problem better managed inside a focused drug company than buried within a sprawling conglomerate. At separation AbbVie was effectively a one-product company. Humira, an injectable antibody that suppresses an inflammatory protein called TNF, treated rheumatoid arthritis, psoriasis, Crohn's disease, and a growing list of other autoimmune conditions, and it threw off enormous and highly profitable cash flow. The entire strategic history of AbbVie since 2013 can be read as a long effort to convert that cash flow into a more durable and diversified business before the patent protection ran out.

The defining commercial event arrived in January 2023, when Humira lost its United States patent protection and biosimilar copies entered the market. Humira sales fell sharply and have continued to erode as lower-priced competitors take share, the classic shape of a patent cliff. What separates AbbVie from many companies that have faced the same fate is that the replacement engine was already running. Skyrizi, which treats psoriasis and inflammatory bowel disease, and Rinvoq, an oral drug for rheumatoid arthritis, atopic dermatitis, and a widening set of immune conditions, were launched years before the Humira cliff specifically to inherit its franchise. The handoff has worked better than most observers expected. The two newer drugs together produced combined sales of roughly twenty-six billion dollars in 2025, growing more than forty percent year over year, and management has guided that the pair should exceed thirty billion dollars in combined sales by 2027. In a single product cycle AbbVie replaced its most important drug with two drugs that, taken together, are now larger than Humira ever was.

The second pillar of the modern company came from acquisition rather than internal research. In 2020 AbbVie closed its purchase of Allergan for roughly sixty-three billion dollars, the largest deal in its history and an explicit move to diversify away from immunology before the Humira cliff. Allergan brought two distinct businesses. The first was a neuroscience portfolio, including the migraine treatment Ubrelvy and the antipsychotic Vraylar, that gave AbbVie a meaningful presence in brain disorders. The second was a global aesthetics business built around Botox, the wrinkle treatment that is also sold as a therapeutic for migraine and muscle disorders, along with the dermal filler line Juvederm. Aesthetics gave AbbVie something unusual for a drugmaker, a portfolio of cash-pay consumer products sold through dermatologists and medical spas rather than reimbursed by insurers. That cash-pay nature is a double-edged feature. It frees the business from some of the pricing pressure that weighs on prescription drugs, but it also ties demand to consumer discretionary spending, and aesthetics revenue has softened during periods of economic caution, with Botox Cosmetic and especially Juvederm posting declines through 2025.

Beyond immunology and aesthetics, AbbVie has steadily widened its oncology and neuroscience franchises. In cancer the company sells the blood-cancer drugs Imbruvica and Venclexta, and it acquired ImmunoGen in 2024 to add antibody-drug conjugate technology, a method of delivering toxic payloads directly to tumor cells. In neuroscience the Botox therapeutic franchise and Vraylar are large and growing, and AbbVie acquired Cerevel Therapeutics for roughly eight billion dollars to deepen its pipeline in schizophrenia, Parkinson's disease, and mood disorders, though one of Cerevel's most watched candidates, a schizophrenia drug called emraclidine, failed its main trials shortly after the deal closed and was written down. That outcome is a reminder that pipeline acquisitions carry real scientific risk even when the price is large. More recently the company has pushed into newer areas, licensing an experimental obesity drug from Gubra to enter the crowded weight-loss field and buying Capstan Therapeutics and Aliada Therapeutics to add next-generation immunology and Alzheimer's technology.

The economic engine that makes all of this possible is the high-margin, patent-protected nature of branded biologic drugs. A successful biologic can sell for many thousands of dollars per patient per year while costing a fraction of that to manufacture, and patent protection holds competitors off for roughly a decade or more after launch. The barrier to entry is steep. Bringing a new drug from discovery through clinical trials and regulatory approval costs well over a billion dollars and takes many years, and most candidates fail somewhere along the way. AbbVie funds an enormous research and business-development budget out of its drug profits, spending heavily each year on its own laboratories and on acquisitions and licensing deals, which is how a company built on one aging blockbuster keeps generating the next generation of products. The moat is the combination of patents, scientific know-how, regulatory expertise, and the scale to run global trials and sales organizations that smaller rivals cannot match.

Competition is specific to each franchise rather than companywide. In immunology AbbVie faces the other large makers of autoimmune drugs, including Johnson & Johnson, whose Tremfya competes directly with Skyrizi, along with Pfizer, Eli Lilly, Bristol Myers Squibb, and a long line of Humira biosimilar producers. In oncology it contends with Roche, Merck, AstraZeneca, and many others fielding their own cancer pipelines. In neuroscience it competes with both established drugmakers and specialists. In aesthetics Botox faces rival neurotoxins such as Dysport and Xeomin, ironically two products that Allergan itself once competed against, along with newer entrants, and the filler market is similarly crowded. Across all of these arenas the sharpest recurring threat is the same one that defined the Humira story, the loss of exclusivity that lets cheaper copies erode a once-dominant product.

Leadership sits with Robert Michael, who became chief executive in 2024 after serving as president and chief operating officer and, before that, chief financial officer. Michael is a long-tenured insider who spent years inside AbbVie's finance and operations organizations before taking the top job, and he succeeded Richard Gonzalez, the founding chief executive who led the company through the spinoff, the Allergan acquisition, and the Humira transition. The continuity is deliberate. AbbVie's strategy has been remarkably consistent across the handover, namely to defend and grow the Skyrizi and Rinvoq franchises, to diversify through disciplined acquisitions, and to keep replacing patent-expiring revenue faster than it fades. The company also pays a large and steadily rising dividend, a legacy of its Abbott heritage, and it treats that dividend as a core part of its identity and its appeal to long-term holders.

The risks are real and concentrated in a familiar pattern. The largest is repetition of the Humira cliff itself. Skyrizi and Rinvoq are now the company's most important products, and they too will eventually lose patent protection toward the middle of the next decade, which means AbbVie must once again build the next wave of replacements before the current one peaks and declines. Pipeline failures like the emraclidine write-down show that the replacements are not guaranteed. Beyond exclusivity, the company faces government pressure on drug pricing in the United States, including the Medicare price negotiation provisions that target older high-revenue drugs, potential tariffs on pharmaceutical manufacturing, the discretionary-spending sensitivity of the aesthetics business, and the integration and impairment risk that comes with a strategy so dependent on large acquisitions. The debt taken on to buy Allergan also left the company more leveraged than some peers, though strong cash generation has steadily reduced that burden.

The way to weigh AbbVie is as a company that has proven, more clearly than almost any of its peers, that it can survive the loss of a defining blockbuster, and that now has to prove it can do so again. The Humira-to-Skyrizi-and-Rinvoq handoff was an unusually successful execution of the hardest problem in the drug business, replacing irreplaceable revenue, and it left AbbVie more diversified across immunology, oncology, neuroscience, and aesthetics than it was at its founding. The same story also frames the central uncertainty. The company's value rests heavily on two drugs that face their own patent cliffs within a decade, on an acquisition machine that has produced both wins and write-downs, and on a pricing and regulatory environment that grows less forgiving toward high-revenue medicines. The question for an investor is whether AbbVie's demonstrated skill at managing patent cliffs and refilling its pipeline is durable enough to repeat through the next cycle, or whether the first great handoff was a one-time achievement that will be harder to reproduce as the easy diversification moves are exhausted.